



# International Gastroenterology Conference

May 15-16, 2019 Amsterdam, Netherlands

## FERALGINE™ A New Approach for Iron Deficiency Anemia in Coeliac Patients

Marco Bertini<sup>1\*</sup>, Laura Giacotti<sup>2</sup>, Giuseppe Mazza<sup>2</sup>, Santina Marrasso<sup>2</sup>, Valentina Tallarico<sup>2</sup>, Pietro Cangemi<sup>3</sup> and Roberto Miniero<sup>2</sup>

<sup>1</sup>R&D Dept Laboratori Baldacci SpA, Italy

<sup>2</sup>Unit of Paediatrics, University Magna Grecia, Pugliese-Ciaccio Hospital, Italy

<sup>3</sup>Medical Laboratory, University Magna Grecia, Pugliese-Ciaccio Hospital, Italy

**Background:** Coeliac Disease (CD) is an immune mediated disorder largely focused in the proximal small intestine mucosa. Reduced iron absorption because of duodenal mucosa villi atrophy is often present in coeliac patients making every kind of oral iron treatment unuseful because of malabsorption. FERALGINE™ is a new patented co-processed 1 to 1 ratio compound between Ferrous Bysglycinate and Sodium Alginate that has been demonstrated to be almost four times more oral bioavailable than Ferrous Sulphate.

**Methods:** 25 Adults affected by Iron Deficiency Anemia (IDA) of which 14 affected also by Coeliac Disease (aged 33 years, Hb 11.5 g/dl) and 11 without Coeliac Disease (aged 32.16 years, Hb 11.3 g/dl) has been enrolled in the trial. Oral Iron Absorption Test (OIAT) by using only 60 mg of elemental iron belonging to FERALGINE™ has been acutely used in every patients and serum iron was evaluated at baseline (T0) and after 2 hours (T1) from the oral iron ingestion.

**Results:** OIAT was well tolerated in every patients and surprising, an equivalent statistically significant improvement in serum iron occurred after two hours in the two groups of patients (IDA plus CD: T0 = 28.21 µg/dl vs T1 = 92.71 µg; p = 0.004 T Student's Test and IDA without CD: T0 = 37.09 µg vs T1 = 125.54 µg; p = 0.001 T Student's Test)

**Conclusions:** These results obtained by OIAT clearly demonstrated the high bioavailability of FERALGINE™ also in coeliac patients only after two hours of treatment confirming the previous data obtaining with Ferrous Bysglycinate alone and with FERALGINE™.

### Biography:

Marco Bertini was born in Pisa, Italy, in 1960. He graduated in Medicine & Surgery in Pisa University in 1987. He has a PhD in Paediatrics and a PhD in Clinical Pharmacology. He was working in Pharmaceutical Companies as Medical Manager since 1990 and He was teaching Clinical Pharmacology as Contract Professor in Pisa University. He was Editorial Board Member of several international Journals and He was Author of more than 100 impacting international scientific articles. He was attending a lot of international Congresses like "invited speaker" all over the world in different scientific topics (cardiology, gastroenterology, metabolism and Diabetes, Alcoholism, Iron Deficiency Anemia). He was actually employed in Laboratori Baldacci SpA, Pisa, Italy as Medical Affairs Manager.